胃癌中琥珀酸脱氢酶自身抗体的阶段特异性改变及其与预后的关系。

Stage-Specific Alteration and Prognostic Relationship of Serum Fumarate Hydratase Autoantibodies in Gastric Cancer.

机构信息

Department of Gastroenterological Surgery, Toho University School of Medicine, Tokyo 143-8541, Japan.

Department of Clinical Oncology, Toho University Graduate School of Medicine, Tokyo 143-8541, Japan.

出版信息

Int J Mol Sci. 2024 May 17;25(10):5470. doi: 10.3390/ijms25105470.

DOI:10.3390/ijms25105470

PMID:38791507

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11121488/

Abstract

The relationship between energy production and cancer is attracting attention. This study aimed to investigate the clinicopathological significance of fumarate hydratase (FH), a tricarboxylic acid cycle enzyme, in gastric cancer using autoantibodies as biomarkers. The study analyzed 116 patients who underwent gastric cancer surgery and 96 healthy controls. Preoperative serum FH autoantibody (s-FH-Ab) titers were analyzed using an immunosorbent assay with an amplified luminescent proximity homogeneous assay. Receiver operating characteristic analysis was used to determine the cutoff s-FH-Ab titer. Clinicopathological factors and prognosis were compared between the high and low s-FH-Ab groups. The s-FH-Ab levels were significantly higher in the gastric cancer group than in the control group ( = 0.01). Levels were elevated even in patients with stage I gastric cancer compared with healthy controls ( = 0.02). A low s-FH-Ab level was significantly associated with distant metastasis ( = 0.01), peritoneal dissemination ( < 0.05), and poor overall survival ( < 0.01). Multivariate analysis revealed that low s-FH-Ab levels were an independent risk factor for poor prognosis ( < 0.01). Therefore, s-FH-Ab levels may be a useful biomarker for early diagnosis and the prediction of prognosis in patients with gastric cancer.

摘要

能量产生与癌症之间的关系正引起关注。本研究旨在使用自身抗体作为生物标志物，探讨三羧酸循环酶富马酸水合酶（FH）在胃癌中的临床病理意义。该研究分析了 116 例接受胃癌手术的患者和 96 例健康对照者。使用带有放大发光近同相分析的免疫吸附测定法分析了术前血清 FH 自身抗体（s-FH-Ab）滴度。采用受试者工作特征分析确定 s-FH-Ab 滴度的截断值。比较了高 s-FH-Ab 和低 s-FH-Ab 组之间的临床病理因素和预后。与对照组相比，胃癌组的 s-FH-Ab 水平明显更高（ = 0.01）。与健康对照组相比，甚至在 I 期胃癌患者中 s-FH-Ab 水平也升高（ = 0.02）。低 s-FH-Ab 水平与远处转移（ = 0.01）、腹膜播散（ < 0.05）和总体生存不良（ < 0.01）显著相关。多变量分析显示，低 s-FH-Ab 水平是预后不良的独立危险因素（ < 0.01）。因此，s-FH-Ab 水平可能是胃癌早期诊断和预后预测的有用生物标志物。